title: Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke.
abstract: OBJECTIVE
  To evaluate whether the presence of leukoaraiosis or multiple lacunes is associated with symptomatic intracerebral hemorrhage (ICH) and 90-day outcome after thrombolytic treatment with tissue plasminogen activator (tPA).
  
  
  METHODS
  Data were from a Canadian national registry of thrombolyzed patients with ischemic stroke. A total of 820 scans were assessed, blind to clinical features, for the presence of severe vs no/moderate leukoaraiosis, and of multiple (>2) vs no/single lacunar infarcts. Logistic regression was used to determine if an independent interaction existed between the presence and degree of leukoaraiosis/lacunes and risk of symptomatic ICH, and to evaluate the predictive role of leukoaraiosis and lacunes in relation to 90-day outcome.
  
  
  RESULTS
  An overall symptomatic ICH rate of 3.5% was observed. The rate of symptomatic ICH increased up to 10% in patients with severe leukoaraiosis and multiple lacunes. A significant association was observed between ICH risk and either severe leukoaraiosis (RR = 2.7 [95% CI 1.1 to 6.5]) or multiple lacunes (RR = 3.4 [95% CI 1.5 to 7.6]). Patients with multiple lacunes, but not leukoaraiosis, had higher mortality at 90 days compared to those with one or no lacunes (OR = 2.9, 95% CI 1.3 to 6.2, p = 0.008). No difference was observed in the good outcome rate among patients with and without leukoaraiosis or lacunes or both.
  
  
  CONCLUSIONS
  The presence of small vessel disease on CT scan does not affect overall clinical outcome at 3 months in routine community use of tPA for ischemic stroke. A significant increase in the risk of symptomatic ICH is observed.
authors: Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy. vanessa.palumbo@unifi.it
authors: V
authors: V
authors: Palumbo
authors: J M
authors: JM
authors: Boulanger
authors: M D
authors: MD
authors: Hill
authors: D
authors: D
authors: Inzitari
authors: A M
authors: AM
authors: Buchan
mesh_terms: D000208:Acute Disease / Q000628:therapy; D000368:Aged; D001921:Brain / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology; D020520:Brain Infarction / Q000150:complications / Q000473:pathology / Q000503:physiopathology; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D002170:Canada; D002536:Cerebral Arteries / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology; D015331:Cohort Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects; D006801:Humans; D049292:Leukoaraiosis / Q000150:complications* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009413:Nerve Fibers, Myelinated / Q000473:pathology; D011446:Prospective Studies; D012189:Retrospective Studies; D012307:Risk Factors; D020521:Stroke / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator